In a groundbreaking development, Unity and AMILI have joined forces to launch a revolutionary synbiotic product, AMILI Metabolic Health, tailored specifically for Asian gut microbiomes. This collaboration aims to address the unique metabolic health challenges faced by Asian populations, and it's an exciting step forward in personalized nutrition.
The Asian Gut Microbiome Advantage
What makes this product truly innovative is its foundation in Asian gut microbiome data. By analyzing data from Singapore's National University Hospital (NUH) and AMILI's Asian Microbiome Library, the formulation considers the distinct microbial profiles of Asian individuals. As Dr. Jeremy Lim, co-founder and CEO of AMILI, highlights, "An Asian gut is not the same as a Western one." This recognition of cultural and dietary differences is a game-changer in the supplement industry.
A Synbiotic Approach for Metabolic Health
The synbiotic nature of AMILI Metabolic Health is a key differentiator. While consumers are familiar with the gut benefits of probiotics, the synergy between probiotics, prebiotics, and postbiotics in synbiotics is less understood. Unity, through its extensive pharmacist network, aims to educate the public on these benefits. Pauline Png, General Manager at Unity, emphasizes the Asian-specificity of the formulation, making it a unique offering in the market.
The Science Behind the Formulation
The R&D process involved a comprehensive analysis of microbiome data from healthy individuals and patients. Dr. Lim explains their functional pathway approach, studying the microbes and their interactions to identify beneficial strains for metabolic health. The resulting formulation includes four probiotic strains, a postbiotic, prebiotic fiber, and botanical extracts, each carefully selected for their specific health benefits. For instance, Lactobacillus rhamnosus targets fasting blood glucose and liver function, while Akkermansia improves insulin sensitivity and total cholesterol.
AI-Assisted Optimization
An interesting aspect is the use of an AI model to determine the optimal dose and proportion of probiotic strains. This technology-driven approach adds a layer of precision to the formulation, ensuring its effectiveness. The product was further validated against NUS's patient cohort, with positive results on glycemic, lipid, and hepatic endpoints.
Addressing Metabolic Health Challenges in Asia
Metabolic health was chosen as the focus due to its prevalence among Asians. As Dr. Lim points out, even the World Health Organization recognizes the lower BMI thresholds for obesity and overweight in Asian populations. This product aims to address this unique challenge, offering a tailored solution. In Singapore, where metabolic and fatty liver conditions are on the rise, collaborations like this are crucial for advancing our understanding of gut microbiome's role in health and disease.
A Step Towards Personalized Nutrition
This launch is a testament to the growing importance of personalized nutrition. By leveraging Asian-specific microbiome data, Unity and AMILI are offering a targeted solution for a specific demographic. As Associate Professor Dan Yock Young from NUH notes, such collaborations deepen our understanding of the gut microbiome's influence on health and can lead to new approaches for supporting metabolic health in Asian populations.
In my opinion, this is a significant advancement in the field of nutraceuticals, and I'm excited to see the impact it will have on metabolic health management in Asia.
